LRK-4189 optimization

Preclinical

LLARKSPUR BIOSCIENCES, INC.

LRK-4189 optimization is one of 18 therapeutic programs targeting Neoplasms. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

NeoplasmsRecruiting

NeoplasmsPreclinical

Recruiting

Competition

Competitive Landscape

32 competitors in Neoplasms

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

1 2

Tecentriq

Roche

Phase 3

1 3

Taxol

Teva

Phase 3

1 4

Avastin

BBio-Thera Solutions

Phase 3

1 5

Alimta

GGynecologic Oncology Group

Phase 3

1 6

Jakafi

Incyte

Phase 1

1 7

Keytruda

Merck & Co.

Phase 1

1 8

Dostarlimab

Incyte

Phase 1

1 9

Ojjaara

GGlaxo Dba Glaxosmithkline

Phase 1

1 10

Cetrelimab

Johnson & Johnson

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Neoplasms

NCT07498725

Clinical

Trials by Indication[1]

Neoplasms1 trial

A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination With mFOLFOX6 or FOLFIRI in Patients With Solid Tumors

Recruiting·LLARKSPUR BIOSCIENCES, INC.·Preclinical·NCT07498725·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LRK-4189 optimization. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for LRK-4189 optimization. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — LARKSPUR BIOSCIENCES, INC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: LLARKSPUR BIOSCIENCES, INC.

LRK-4189 optimization

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Neoplasms1 trial

References

Drug Info

Quick Facts

Related News